Danaher Corporation (NYSE:DHR) Shares Bought by Great Lakes Retirement Inc.

Great Lakes Retirement Inc. grew its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 7.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 39,687 shares of the conglomerate's stock after acquiring an additional 2,685 shares during the period. Danaher accounts for 1.1% of Great Lakes Retirement Inc.'s portfolio, making the stock its 28th largest holding. Great Lakes Retirement Inc.'s holdings in Danaher were worth $8,136,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of DHR. Cypress Advisory Group LLC increased its position in Danaher by 87.2% in the first quarter. Cypress Advisory Group LLC now owns 2,995 shares of the conglomerate's stock worth $614,000 after buying an additional 1,395 shares in the last quarter. Adero Partners LLC increased its stake in shares of Danaher by 11.2% in the first quarter. Adero Partners LLC now owns 1,953 shares of the conglomerate's stock worth $400,000 after purchasing an additional 197 shares in the last quarter. Sowell Financial Services LLC bought a new stake in shares of Danaher during the 1st quarter valued at $1,442,000. Mission Wealth Management LP lifted its stake in shares of Danaher by 0.7% during the 1st quarter. Mission Wealth Management LP now owns 13,096 shares of the conglomerate's stock valued at $2,685,000 after buying an additional 96 shares in the last quarter. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its holdings in Danaher by 1.6% in the 1st quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 15,107 shares of the conglomerate's stock worth $3,097,000 after buying an additional 241 shares during the period. Institutional investors own 79.05% of the company's stock.

Insider Buying and Selling

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Down 0.7%

Shares of DHR stock traded down $1.39 on Thursday, hitting $194.36. The stock had a trading volume of 3,236,239 shares, compared to its average volume of 3,488,121. The business has a 50 day moving average price of $193.46 and a 200 day moving average price of $210.32. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The company has a market cap of $139.10 billion, a PE ratio of 37.74, a P/E/G ratio of 2.75 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.66%. Danaher's dividend payout ratio is currently 24.85%.

Analyst Ratings Changes

Several brokerages have recently commented on DHR. Deutsche Bank Aktiengesellschaft lowered their price objective on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Wolfe Research cut their price objective on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a report on Monday, April 7th. The Goldman Sachs Group lowered their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Argus dropped their price objective on shares of Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. Finally, Jefferies Financial Group decreased their target price on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus price target of $248.17.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.